STOCK TITAN

Durect Corp - DRRX STOCK NEWS

Welcome to our dedicated news page for Durect (Ticker: DRRX), a resource for investors and traders seeking the latest updates and insights on Durect.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Durect's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Durect's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.22%
Tags
management
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.38%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.16%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.06%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.45%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.03%
Tags
Durect Corp

Nasdaq:DRRX

DRRX Rankings

DRRX Stock Data

23.77M
29.66M
5.97%
22.56%
3.32%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Cupertino

About DRRX

durect is a specialty pharmaceuticals company with expertise in drug discovery, drug delivery and drug development, applying those skills primarily to therapeutics in the fields of pain management, acute organ injury and metabolic diseases. durect’s proprietary oral, transdermal and injectable depot delivery technologies enable new indications and superior clinical/commercial attributes such as improved abuse deterrence, convenience, adherence, efficacy and safety for small molecule and biologic drugs. late stage development programs of this nature include remoxy® and posidur™. durect’s epigenomic regulator program includes the lead molecule dur-928 in phase 1 clinical testing. dur-928 is an endogenous small molecule that is an epigenomic modulator of cellular activities involved in lipid homeostasis, metabolic disease, inflammation and cell survival. for more information, please visit www.durect.com. we also manufacture and sell two commercial product lines: • alzet® osmotic pumps use